₹1,069.05
+0.77%NSE close, 16 Nov 2026
+36.41%
Yatharth Hospital & Trauma Care Services is a small cap company in the Healthcare sector, listed on NSE under the symbol YATHARTH. At ₹1,069.05 a share, the market values the whole company at ₹10,301 crore.
In FY26, it reported sales of ₹1,207 crore and a net profit of ₹170 crore, an operating margin of 24.2%.
The market values the company at 54.9 times its profit over the last twelve months and 5.49 times its book value; its return on equity is 10.0% and its borrowings are 0.24 times its equity.
Promoters hold 55.80% of the shares, and have pledged 9.6% of their holding. Foreign institutions hold 7.05%, and domestic institutions, mutual funds among them, 10.94%.
Over the past year the share price has risen 34.7%, and it is 9.7% below its 52-week high.
Companies of a similar size in the same sector include Metropolis Healthcare, Akums Drugs and Pharmaceuticals, Park Medi World and Viyash Scientific.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
| Metropolis Healthcare | ₹574.15 | ₹11,907 cr | 53.1 | 13.7% | +15.80% | +14.50% |
| Akums Drugs and Pharmaceuticals | ₹722.20 | ₹11,367 cr | 31.2 | 10.4% | +31.90% | +56.88% |
| Park Medi World | ₹245.03 | ₹10,584 cr | 41.3 | 11.9% | n/a | n/a |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 |
We hereby submit Earnings Call Transcript Q2FY27.
We hereby submit intimation regarding the Approval of CCI for the proposed Preferential Issue.
We hereby submit Monitoring Agency Report for the quarter ended September 30, 2026 (IPO).
We hereby submit Earnings Call Recording for Q2FY27.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 167 | 178 | 212 | 218 | 219 | 232 | 258 | 279 | 320 | 342 | 393 | 431 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 120 | 131 | 158 | 163 | 164 | 175 | 193 | 215 | 246 | 262 | 301 | 329 |
| Operating profit | 46.4 | 46.5 | 53.7 | 54.6 | 54.9 | 57.0 | 64.5 | 64.5 | 74.3 | 79.9 | 91.7 | 102 |
| Operating margin | 27.8% | 26.2% | 25.3% | 25.1% | 25.1% | 24.6% | 25.0% | 23.1% | 23.2% | 23.4% | 23.3% | 23.6% |
| Other income | 5.4 | 5.7 | 3.7 | 3.0 | 4.2 | 5.3 | 9.3 | 9.5 | 7.8 | 7.1 | 4.4 | 5.0 |
| Interest | 0.2 | 0.4 | 2.9 | 1.6 | 2.1 | 1.0 | 0.2 | 0.3 | 1.0 | 5.1 | 6.6 | 8.3 |
| Depreciation | 7.9 | 7.7 | 11.4 | 16.0 | 16.9 | 12.9 | 14.9 | 18.9 | 24.0 | 30.0 | 28.2 | 33.1 |
| Profit before tax | 43.8 | 44.1 | 43.0 | 40.1 | 40.2 | 48.5 | 58.7 | 54.8 | 57.1 | 52.0 | 61.2 | 65.6 |
| Tax | 14.3 | 5.8 | 12.6 | 9.1 | 9.7 | 9.8 | 16.7 | 13.6 | 14.0 | 7.3 | 15.8 | 17.2 |
| Net profit | 29.5 | 38.4 | 30.4 | 31.0 | 30.5 | 38.7 | 42.0 | 41.2 | 45.4 | 44.7 | 47.1 | 50.6 |
| EPS (₹) | 3.83 | 4.85 | 3.54 | 3.59 | 3.57 | 4.37 | 4.36 | 4.28 | 4.71 | 4.93 | 4.88 | 5.25 |
₹ crore, financial years to March.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales | 670 | 880 | 1,207 |
| Expenses | 490 | 660 | 915 |
| Operating profit | 180 | 220 | 292 |
| Operating margin | 26.8% | 25.0% | 24.2% |
| Other income | 15.6 | 16.2 | 25.8 |
| Interest | 9.4 | 7.5 | 6.5 |
| Depreciation | 29.3 | 57.2 | 87.8 |
| Profit before tax | 157 | 172 | 224 |
| Tax | 42.4 | 41.2 | 53.3 |
| Net profit | 114 | 131 | 170 |
| EPS (₹) | 15.39 | 14.72 | 18.20 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 150 | 205 | 73.1 |
| From investing | −420 | −598 | −177 |
| From financing | 520 | 254 | 158 |
| Spent on fixed assets | −311 | −317 | −237 |
| Free cash flow | −161 | −112 | −164 |
Margins, returns, debt, tax and cash.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net margin | 17.1% | 14.8% | 14.1% |
| Operating margin | 26.8% | 25.0% | 24.2% |
| Return on equity | 13.1% | 8.1% | 9.4% |
| Return on capital employed | 17.4% | 11.2% | 11.2% |
| Return on assets | 11.2% | 7.5% | 7.5% |
| Debt to equity | 0.09 | 0.00 | 0.14 |
| Interest coverage | 17.60 | 23.90 | 35.20 |
| Debt to assets | 0.08 | 0.00 | 0.11 |
| Current ratio | 7.59 | 10.12 | 3.87 |
| Quick ratio | 7.47 | 9.87 | 3.76 |
| Cash ratio | 1.68 | 4.28 | 1.20 |
| Asset turnover | 0.66 | 0.51 | 0.53 |
| Fixed asset turnover | 1.76 | 1.79 | 1.34 |
| Inventory turnover | 16.40 | 8.50 | 11.30 |
| Receivables turnover | 3.00 | 2.90 | 3.20 |
| Gross margin | 80.1% | 79.7% | 80.6% |
| Cash from operations to profit | – | 115.0% | 120.0% |
| Effective tax rate | 27.0% | 24.0% | 23.8% |
| 7.3% |
| +133.00% |
| +9.21% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
|---|
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
|---|
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
|---|
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
|---|
We hereby submit Press Release for Financial Results for Q2FY27.
We hereby submit Outcome of the Board Meeting of the Company held on today. i.e. November 03, 2026.
We hereby submit Schedule of Earnings Conference Call Q2FY27.
We hereby submit Voting Results and Srutinizer Report of the 1st/2026-27 Extraordinary General Meeting held on October 15, 2026.
We hereby submit the summary of Proceedings of the 1st/2026-27 Extra-Ordinary General Meeting of the Company held today i.e. October 15, 2026.
We hereby submit Corrigendum to the Notice of the 1st/2026-27 Extra Ordinary General Meeting to be held on October 15, 2026.
We hereby submit Voting Results and Scrutinizer Report of the 19th Annual General Meeting held on September 25, 2026.
We hereby submit the summary of the Proceedings of 19th Annual General Meeting of the Company held today i.e. September 25, 2026.
We hereby submit intimation regarding Schedule of Analyst/Investor Meet.
We hereby submit Notice of 1st/2026-27 Extra-Ordinary General Meeting of the Company.